智通财经网·2026-01-30 01:53Core Viewpoint - Spring Medical (01858) has shown a significant increase in stock price and is expected to report substantial profit growth for the fiscal year 2025, indicating strong operational performance and strategic initiatives [1] Financial Performance - The company forecasts a net profit attributable to shareholders of RMB 245 million to RMB 288 million for 2025, representing an increase of RMB 120 million to RMB 163 million compared to the previous year, which is a year-on-year growth of 96.01% to 130.41% [1] - The net profit attributable to shareholders after excluding non-recurring gains and losses is expected to be between RMB 230 million and RMB 270 million, reflecting an increase of RMB 135 million to RMB 175 million year-on-year, translating to a growth of 142.80% to 185.11% [1] Strategic Initiatives - The company attributes its expected profit growth to the gradual release of growth potential across its product lines following the inclusion in centralized procurement [1] - Spring Medical is committed to an international development strategy and is steadily advancing its international business layout, which supports sustained and healthy revenue growth [1] - The company is focusing on enhancing operational management, optimizing resource allocation, and improving overall efficiency and profitability, which are crucial for supporting its performance growth [1]